NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
about
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialSaponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formationMelanoma: tumor microenvironment and new treatments.Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.Preclinical development of HIvax: Human survivin highly immunogenic vaccinesTurbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neckIn silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.Optimization of norovirus virus-like particle production in Pichia pastoris using a real-time near-infrared bioprocess monitor.Translational nanoparticle engineering for cancer vaccines.Enhancing tumor specific immune responses by transcutaneous vaccination.A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients.Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer
P2860
Q26769884-88A7B1E8-65AC-428A-8EB6-BCCD73DDE237Q28393754-18ACB7A1-134C-4C81-836E-8B36BD3A71F5Q33675676-89872081-B343-442C-B47E-BE5C84951FE4Q36009558-265D2CBC-D942-4D3E-BE4F-A47B92EC4DBDQ38445350-91608403-C538-481C-9736-6D0E027F9A66Q38867680-A9335AE8-BCC9-483B-B44C-AC9BD92732BEQ39450802-34A5FEC6-426D-4FE5-9491-521ACBF0C64EQ39999283-7E4CB589-28DC-44A0-A22E-EBC4C2D047C1Q40188864-804AD68B-6269-4E0B-91E7-E5BB9AFAA539Q40988893-8C82E324-DAE3-4052-8800-7E468AF2BBBAQ46720677-5846B9F5-1E9B-4044-8D47-9567876E39E7Q49932505-331D8D98-F6C3-4AAE-A92E-14E990ADA941Q52822549-EE639282-5F65-4037-8183-A586D4435198Q55136811-A6814D16-62D0-45B6-8D59-3DC791BD0DF1Q57072901-497A096D-E4BE-4690-B541-F1ECA1A18CD8
P2860
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
NY-ESO-1 specific antibody and ...... binant NY-ESO-1 fowlpox virus.
@en
NY-ESO-1 specific antibody and ...... binant NY-ESO-1 fowlpox virus.
@nl
type
label
NY-ESO-1 specific antibody and ...... binant NY-ESO-1 fowlpox virus.
@en
NY-ESO-1 specific antibody and ...... binant NY-ESO-1 fowlpox virus.
@nl
prefLabel
NY-ESO-1 specific antibody and ...... binant NY-ESO-1 fowlpox virus.
@en
NY-ESO-1 specific antibody and ...... binant NY-ESO-1 fowlpox virus.
@nl
P2093
P2860
P50
P356
P1476
NY-ESO-1 specific antibody and ...... binant NY-ESO-1 fowlpox virus.
@en
P2093
Abdelouahid Tajar
Amina Dawoodji
Andrea Tarlton
Christian Verfaille
Douglas G Altman
Ji-Li Chen
Judy Browning
Lloyd L Old
Mark Middleton
P2860
P304
P356
10.1002/IJC.29118
P577
2014-08-14T00:00:00Z